Treatment principles for the management of mold infections.
Survival rates among immunocompromised patients with invasive mold infections have markedly improved over the last decade with earlier diagnosis and new antifungal treatment options. Yet, increasing antifungal resistance, breakthrough infections with intrinsically resistant fungi, and potentially life-threatening adverse effects and drug interactions are becoming more problematic, especially with prolonged therapy. Evidence-based recommendations for treating invasive aspergillosis and mucormycosis provide excellent guidance on the initial workup and treatment of these molds, but they cannot address all of the key management issues. Herein, we discuss 10 general treatment principles in the management of invasive mold disease in immunocompromised patients and discuss how these principles can be integrated to develop an effective, individualized treatment plan.
The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030.
Dimitrios P
DP
Kontoyiannis
Department of Medical Sciences and Surgery, University of Bologna, 40138 Bologna, Italy.
Russell E
RE
Lewis
D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy*; D019468:Disease Management; D005658:Fungi / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D009091:Mucormycosis / Q000175:diagnosis / Q000188:drug therapy*
D000935:Antifungal Agents